VEGFA and chronic asthma: The present study examined the anti-remodeling and anti- inflammatory effects of BIBF1000, a triple-tyrosine kinase inhibitor that targets VEGF, PDGF, and FGF receptor signaling in an experimental model of chronic asthma.